Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis

Figure 2

Kaplan-Meier curves showing overall survival (OS) and progression-free survival (PFS) in the unmatched groups of patients who received conventional transarterial chemoembolization (cTACE) and hepatic arterial infusion chemotherapy (HAIC) in combination or cTACE only. (a) OS in the unmatched cohort. OS was significantly longer for the patients who were treated with cTACE and HAIC than that for the patients who received cTACE only in the unmatched cohort (). (b) PFS in the unmatched cohort. PFS was longer for the patients who received cTACE and HAIC compared with that for the patients who received cTACE alone (). (c) OS in the matched cohort. OS was significantly longer for the patients who received cTACE and HAIC than for the patients who received cTACE alone in the matched cohort (). (d) PFS in the matched cohort. PFS was significantly longer for the patients who received cTACE and HAIC than for the patients who received cTACE alone in the matched cohort (). TACE: transcatheter arterial chemoembolization; HAIC: hepatic arterial infusion chemotherapy.

(a)

(b)

(c)

(d)